US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump - Reuters
US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters
US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters